High-risk morphological features are less prevalent among small (<5mm) papillary thyroid microcarcinomas compared to larger (≥5mm) tumors: a study of 206 cases
References
- 1. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”-screening and overdiagnosis. N Engl J Med. 2014;371:1765-1767.10.1056/NEJMp140984125372084
- 2. Cramer JD, Fu PF, Harth KC et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery. 2010;148: 1147-1152.10.1016/j.surg.2010.10.01621134545
- 3. Davies L,Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317-322.10.1001/jamaoto.2014.124557566
- 4. Pusztaszeri MP, Tamilia M, Payne RJ. Active surveillance for low-risk small papillary thyroid cancer in North American countries: past, present and future (bridging the gap between North American and Asian practices). Gland Surg. 2020;9:1685-1697.10.21037/gs-20-389766705233224846
- 5. Yan L, Blanco J, Reddy V et al. Clinicopathological features of papillary thyroid microcarcinoma with a diameter less than or equal to 5mm. Am J Otolaryngol. 2019;40:560-563.10.1016/j.amjoto.2019.05.00331103218
- 6. Zahan AE, Nechifor-Boilă AC, Paşcanu I, et al. Papillary Thyroid Microcarcinomas: a 25 Years Retrospective, Institutional Study of 255 Cases. Acta Marisiensis - Seria Medica. 2016;62:41-46.10.1515/amma-2015-0108
- 7. Welch HG. Cancer Screening, Overdiagnosis, and Regulatory Capture. JAMA Intern Med. 2017;177:915-916.10.1001/jamainternmed.2017.119828492850
- 8. Vaccarella S, Franceschi S, Bray F et al., Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med. 2016;375:614-617.10.1056/NEJMp160441227532827
- 9. Wang M, Wu WD, Chen GM, et al., Could Tumor Size Be A Predictor for Papillary Thyroid Microcarcinoma: a Retrospective Cohort Study. Asian Pac J Cancer Prev. 2015;16:8625-8628.10.7314/APJCP.2015.16.18.862526745127
- 10. Haugen BR, Alexander EK, Bible KC et al., 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.10.1089/thy.2015.0020473913226462967
- 11. Gong Y, Li G, Lei J et al. A favorable tumor size to define papillary thyroid microcarcinoma: an analysis of 1176 consecutive cases. Cancer Manag Res. 2018;10:899-906.10.2147/CMAR.S154135593119929740219
- 12. Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017;317:1338-1348.10.1001/jama.2017.2719821677228362912
- 13. Kaliszewski K, Diakowska D, Wojtczak B et al. Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? World J Surg Oncol. 2019;17:91.
- 14. Liu C, Wang S, Zeng W et al. Total tumour diameter is superior to unifocal diameter as a predictor of papillary thyroid microcarcinoma prognosis. Sci Rep. 2017;7:1846.10.1038/s41598-017-02165-6543197228500312
- 15. Xu D, Lv X, Wang S et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol. 2014;7:6199-205.
- 16. Virk RK, Van Dyke AL, Finkelstein A et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol. 2013;26:62-70.10.1038/modpathol.2012.15222918165
- 17. Jiang J, Lu H. Immediate Surgery Might Be a Better Option for Subcapsular Thyroid Microcarcinomas. Int J Endocrinol. 2019;2019:3619864.10.1155/2019/3619864647043531073306
- 18. Rosai J, Albores Saavedra J, Asioli S et al. Papillary thyroid carcinoma in Lloyd RV, Osamura RY, Klöppel G et al. (eds): WHO classification of tumours of endocrine organs. 4th edition. International Agency for Research on Cancer (IARC), Lyon, France, 2017, 81-91.
- 19. Sobin LH, Gospodarowicz MK, Wittekind C. UICC/TNM Classification of Malignant Tumors. 7th edition. John Wiley & Sons. Oxford, UK, 2009, 58-62.10.1002/9780471420194.tnmc08.pub2
- 20. Brierley JD, Gospodarowicz MK, Wittekind C. UICC/TNM Classification of Malignant Tumors. 8th edition. John Wiley & Sons. Oxford, UK, 2017, 51-55.10.1002/9780471420194.tnmc09.pub3
- 21. Niemeier LA, Akatsu HK, Song Chi et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118:2069-2077.10.1002/cncr.26425322964921882177
- 22. Finkelstein A, Levy GH, Hui P et al. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology. 2012;60:1052-1059.10.1111/j.1365-2559.2011.04149.x22335197
- 23. Rossi ED, Bizzarro T, Martini M et al., Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience. Cancer Cytopathol. 2014;122:883-8891.10.1002/cncy.2147525156883
- 24. Wada N, Duh QY, Sugino K et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399-407.10.1097/01.SLA.0000055273.58908.19151431212616125
- 25. Shi C, Guo Y, Lv Y et al. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors. PLoS One. 2016;11:e0167414.10.1371/journal.pone.0167414514786927936049
- 26. Qian K, Guo K, Zheng X et al. Contrastive study of two screening criteria for active surveillance in patients with low-risk papillary thyroid microcarcinoma: a retrospective analysis of 1001 patients. Oncotarget. 2017;8:65836-65846.10.18632/oncotarget.19503563037629029476
- 27. Miyauchi A. Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid. World J Surg. 2016;40:516-522.10.1007/s00268-015-3392-y474621326744340
- 28. Zheng X, Peng C, Gao M et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients. Cancer Biol Med. 2019;16:121-130.10.20892/j.issn.2095-3941.2018.0125652846131119052
- 29. Lim YC, Choi EC, Yoon YH et al. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg. 2009;96:253-257.10.1002/bjs.648419224514
- 30. Zhang L, Wei WJ, Ji QH et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012;97:1250-1257.10.1210/jc.2011-154622319042
- 31. Chang YW, Kim HS, Kim HY et al. Should central lymph node dissection be considered for all papillary thyroid microcarcinoma? Asian J Surg. 2016;39:197-201.
- 32. Lombardi CP, Bellantone R, De Crea C et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010;34:1214-1221.10.1007/s00268-009-0375-x20052467
- 33. Pelizzo MR, Boschin IM, Toniato A et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun. 2004;25:547-552.10.1097/01.mnm.0000126625.17166.3615167512
- 34. Song J, Yan T, Qiu W et al. Clinical Analysis of Risk Factors for Cervical Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Retrospective Study of 3686 Patients. Cancer Manag Res. 2020;12:2523-2530.10.2147/CMAR.S250163715399832308489
- 35. Tallini G, De Leo A, Repaci A et al. Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification. Cancers (Basel). 2020;12:246.10.3390/cancers12010246701674331963890
- 36. Ryder M, Ghossein RA, Ricarte-Filho CM J et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-1074.10.1677/ERC-08-0036264861418719091
- 37. Qing W, Fang WY, Ye L et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid. 2012;22:905-910.10.1089/thy.2011.0452342927322870901
- 38. Tao Y. Wang C, Li L et al. Clinicopathological features for predicting central and lateral lymph node metastasis in papillary thyroid microcarcinoma: Analysis of 66 cases that underwent central and lateral lymph node dissection. Mol Clin Oncol. 2017;6:49-55.10.3892/mco.2016.1085524485928123728
- 39. Brito JP, Ito Y, Miyauchi A et al. A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid. 2016;26:144-149.10.1089/thy.2015.0178484294426414743
- 40. Luo Y, Zhao Y, Chen K et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. J Endocrinol Invest. 2019;42:227-236.10.1007/s40618-018-0908-y639476629876836
Language: English
Page range: 108 - 114
Submitted on: Mar 23, 2021
Accepted on: Apr 21, 2021
Published on: Jul 12, 2021
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2021 Emőke-Andrea Szász, Adela Nechifor-Boilă, Ancuța Zahan, Angela Borda, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.